India, April 10 -- Verastem Oncology (VSTM) announced that patients in its Phase 2 RAMP 201 trial of Avutometinib and Defactinib showed sustained clinical benefit with a median follow-up of two years.
The updated analysis, presented at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting, highlighted that 52% of patients with KRAS mutations and 30% of patients with KRAS wild-type recurrent low-grade serous ovarian cancer (LGSOC) remained on therapy for more than one year. Importantly, the combination therapy continued to demonstrate a well-tolerated safety profile, with no new safety signals and signals and low demonstrate a well-tolerated safety profile, with no new safety signals and a low discontinuation rate due to adverse eve...